Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Wafik S. El‐Deiry

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9577-8266; OpenAlex author ID A5075201353. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 15

  1. Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets. Co-author DOI 10.1016/j.mam.2026.101476↗
  2. Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-26-0613↗
  3. Next-Generation Imipridones ONC206 and ONC212 Synergize with Lurbinectedin in Killing Pancreatic Ductal Adenocarcinoma Cells Last author DOI 10.64898/2026.08.13.744614↗
  4. TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcin… Last author DOI 10.62347/roat5658↗
  5. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  6. ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma Last author DOI 10.1101/2024.04.18.590156↗
  7. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancre… Last author DOI 10.62347/dvxl1377↗
  8. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. Last author DOI 10.3390/curroncol30110696↗
  9. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. Last author DOI 10.3390/ijms24044238↗
  10. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  11. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. Last author DOI 10.1080/15384047.2021.1976567↗
  12. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-20-0962↗
  13. Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fphar.2021.751568↗
  14. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  15. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Last author DOI 10.18632/oncotarget.20819↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna D. Louie · 4 shared papers, 2021–2026 · strength 1.01
  2. Attila A. Seyhan · 3 shared papers, 2021–2026 · strength 0.62
  3. Isacco Ferrarini · 2 shared papers, 2021–2026 · strength 0.62
  4. Tej Tummala · 2 shared papers, 2023–2026 · strength 0.56
  5. Vida Tajiknia · 2 shared papers, 2024 · strength 0.47
  6. Howard P. Safran · 2 shared papers, 2021–2026 · strength 0.39
  7. Anthony Frank Shields · 3 shared papers, 2020–2024 · strength 0.37
  8. Alexander Grenander Raufi · 2 shared papers, 2021–2023 · strength 0.36
  9. Davendra P. S. Sohal · 2 shared papers, 2022–2024 · strength 0.29
  10. Emil Lou · 2 shared papers, 2022–2024 · strength 0.29
  11. Thomas J. Miner · 1 shared paper, 2025 · strength 0.27
  12. Andrew Karam · 1 shared paper, 2026 · strength 0.26
  13. Divya Murthy · 1 shared paper, 2026 · strength 0.26
  14. Sendurai A. Mani · 1 shared paper, 2026 · strength 0.26
  15. Razelle Kurzrock · 1 shared paper, 2026 · strength 0.26
  16. Andreas Seeber · 2 shared papers, 2020–2024 · strength 0.26
  17. Heinz‐Josef Lenz · 2 shared papers, 2020–2024 · strength 0.26
  18. Michael S. May · 1 shared paper, 2023 · strength 0.24
  19. William MacDonald · 1 shared paper, 2024 · strength 0.23
  20. Michael J. Hall · 2 shared papers, 2020–2022 · strength 0.20
  21. Wolfgang Michael Korn · 2 shared papers, 2020–2022 · strength 0.20
  22. John Lindsay Marshall · 2 shared papers, 2020–2022 · strength 0.20
  23. Philip A. Philip · 2 shared papers, 2020–2022 · strength 0.20
  24. Sepideh Gholami · 1 shared paper, 2024 · strength 0.17
  25. Erik B. Faber · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.